Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMuhammad Atif KhanFKFaiza Humayun KhanNANausheen Ahmed

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis revealed higher complications in older CAR-T patients, indicating age affects care strategies.

Key Points

  • Older patients experienced higher rates of cytokine release syndrome and encephalopathy compared to younger ones.
  • The analysis identified a total of 3,519 weighted hospitalizations among CAR-T therapy recipients, focusing on age-related outcomes.
  • Retrospective cohort study analyzed outcomes using the National Readmission Database, comparing adults aged ≥65 years to those <65 years.
  • These findings highlight age's role in determining hospitalization complications, suggesting proactive management is necessary.

Cite This Study

Khan et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd13https://doi.org/10.1182/blood-2025-7841
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of age on outcomes of CAR-T cell therapy in multiple myeloma, DLBCL, and follicular lymphoma: A real-world multi-center propensity-matched analysis2025
  2. 2Comparative outcomes of CAR-T therapy in elderly (≥70 Years) versus younger (&amp;lt;70 Years) patients with relapsed/refractory multiple myeloma: A real-world propensity-matched cohort study2025
  3. 3CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma2025
  4. 4Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)2025 · 1 citations
  5. 5Burden and outcomes of CAR T-cell therapy toxicities in DLBCL, multiple myeloma, and B-ALL: A nationwide analysis2025